ENDO PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC.
- Mar 28 2019 |
- Category: CAFC Updates
Endo appeals the district court’s decision holding the claims of U.S. Patent No. 8,808,737 relating to methods of using oxymorphone to treat pain in patients with impaired kidney function in-eligible under 35 U.S.C. § 101. The CAFC finds that the claims are eligible because they are directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome, and notes that CAFC precedent leaves no room for a different outcome. Because the district court incorrectly concluded that the claims at issue are directed to a natural law, the CAFC reverses.